NO20012265L - Dispergerbare preparater inneholdende L-DOPA-ethylester - Google Patents

Dispergerbare preparater inneholdende L-DOPA-ethylester

Info

Publication number: NO20012265L
Authority: NO; Norway
Prior art keywords: ethyl ester; preparations containing; dopa ethyl; dispersible preparations; dispersible
Prior art date: 1998-11-10

Application number

NO20012265A

Other languages

English (en)

Other versions

NO20012265D0 (no

Inventor

Galit Levin

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-11-10

Filing date

2001-05-08

Publication date

2001-07-03

2001-05-08 Application filed by Teva Pharma filed Critical Teva Pharma

2001-05-08 Publication of NO20012265D0 publication Critical patent/NO20012265D0/no

2001-07-03 Publication of NO20012265L publication Critical patent/NO20012265L/no

Links

NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 title 1
238000002360 preparation method Methods 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Psychology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO20012265A 1998-11-10 2001-05-08 Dispergerbare preparater inneholdende L-DOPA-ethylester NO20012265L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US10789398P	1998-11-10	1998-11-10
PCT/US1999/026546 WO2000027385A1 (en)	1998-11-10	1999-11-10	Dispersible compositions containing l-dopa ethyl ester

Publications (2)

Publication Number	Publication Date
NO20012265D0 NO20012265D0 (no)	2001-05-08
NO20012265L true NO20012265L (no)	2001-07-03

Family

ID=22319025

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20012265A NO20012265L (no)	1998-11-10	2001-05-08	Dispergerbare preparater inneholdende L-DOPA-ethylester

Country Status (13)

Country	Link
US (2)	US6376545B1 (no)
EP (1)	EP1135118A1 (no)
JP (1)	JP2002529407A (no)
CN (1)	CN1329487A (no)
AU (1)	AU764742B2 (no)
CA (1)	CA2350304A1 (no)
HK (1)	HK1041441A1 (no)
HU (1)	HUP0104586A3 (no)
IL (1)	IL143071A0 (no)
NO (1)	NO20012265L (no)
NZ (1)	NZ512027A (no)
WO (1)	WO2000027385A1 (no)
ZA (1)	ZA200103527B (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ512027A (en)	1998-11-10	2004-04-30	Teva Pharma	Dispersible compositions containing L-dopa ethyl ester
IL159813A0 (en) *	2001-07-12	2004-06-20	Teva Pharma	Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
WO2003041646A2 (en)	2001-11-13	2003-05-22	Teva Pharmaceutical Industries, Ltd.	L-dopa ethyl ester salts and uses thereof
US20050147670A1 (en) *	2002-05-29	2005-07-07	Impax Laboratories Inc.	Oral disintegrating dosage forms
WO2004100929A1 (en)	2003-05-12	2004-11-25	Synergia Pharma, Inc.	Threo-dops controlled release formulation
US8158149B2 (en) *	2004-05-12	2012-04-17	Chelsea Therapeutics, Inc.	Threo-DOPS controlled release formulation
US8815950B2 (en)	2003-08-29	2014-08-26	Janssen Biotech, Inc.	Pharmaceutical compositions and method of using levodopa and carbidopa
DE602004031134D1 (de) *	2003-08-29	2011-03-03	Transform Pharmaceuticals Inc	Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
US20070010584A1 (en) *	2003-09-04	2007-01-11	Peroutka Stephen J	Compositions and methods for orthostatic intolerance
US20080063720A1 (en) *	2004-04-29	2008-03-13	Gounko Iouri K	Delivery System
WO2006035414A2 (en) *	2004-09-30	2006-04-06	Ranbaxy Laboratories Limited	Carbidopa and levodopa dispersible tablets
CA2613631A1 (en) *	2005-06-23	2007-01-04	Spherics, Inc.	Improved dosage forms for movement disorder treatment
US20080131492A1 (en) *	2006-06-23	2008-06-05	Spherics, Inc.	Dosage forms for movement disorder treatment
WO2008003028A2 (en) *	2006-06-28	2008-01-03	Chelsea Therapeutics, Inc.	Pharmaceutical compositions comprising droxidopa
AU2007338631A1 (en) *	2006-12-22	2008-07-03	Combinatorx, Incorporated	Pharmaceutical compositions for treatment of parkinson's disease and related disorders
ES2500053T3 (es) *	2007-03-09	2014-09-29	Chelsea Therapeutics, Inc.	Composición farmacéutica que comprende droxidopa para el tratamiento de la fibromialgia
JP2010526820A (ja) *	2007-05-07	2010-08-05	チェルシー・セラピューティクス，インコーポレイテッド	気分障害、睡眠障害、または注意欠陥障害を治療するドロキシドパおよびその医薬組成物
BRPI1007855B1 (pt)	2009-05-19	2020-03-10	Celgene Corporation	Formas de dosagem oral compreendendo 4-amino-2-(2,6-dioxopiperidina-3-il)isoindolina-1,3-diona
US20130017274A1 (en) *	2011-03-16	2013-01-17	Buck Institute For Research On Aging	Low dose lithium in the treatment or prophylaxis of parkinson's disease
JP5880913B2 (ja)	2011-05-17	2016-03-09	三郎佐古田	パーキンソン病の体幹症状（姿勢反射異常）の治療剤
US10987313B2 (en)	2013-10-07	2021-04-27	Impax Laboratories, Llc	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
CN105658211A (zh)	2013-10-07	2016-06-08	怡百克制药公司	左旋多巴和/或左旋多巴的酯的粘膜粘附性、控制释放调配物和其用途
JP6622310B2 (ja) *	2014-09-04	2019-12-18	ロブソル・ファーマシューティカルズ・アクチボラグＬｏｂｓｏｒＰｈａｒｍａｃｅｕｔｉｃａｌｓＡｋｔｉｅｂｏｌａｇ	レボドパ、ドーパミン脱炭酸酵素阻害薬およびｃｏｍｔ阻害薬を含む医薬組成物ならびにその投与方法
CN113197851A (zh)	2015-05-06	2021-08-03	辛纳吉勒公司	包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
RU2697411C2 (ru) *	2017-10-11	2019-08-14	федеральное государственное автономное образовательное учреждение высшего образования Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения Российской Федерации (Сеченовский университет)	Композиция для лечения болезни Паркинсона
KR20230124622A (ko)	2020-12-22	2023-08-25	암닐 파마슈티컬스 엘엘씨	레보도파 투여 요법
US11986449B2 (en)	2020-12-22	2024-05-21	Amneal Pharmaceuticals Llc	Levodopa dosing regimen
US11291701B1 (en) *	2021-02-04	2022-04-05	Seed Edibles	Orally disintegrating, sublingual and buccal formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA716958B (en)	1970-10-30	1973-01-31	Hoffmann La Roche	Phenylalanine amides
US3803120A (en)	1971-09-28	1974-04-09	Hoffmann La Roche	Di-and tripeptides of 3-(3,4-dihydroxyphenyl)-alanine
DE2246013A1 (de)	1972-09-20	1974-03-28	Boehringer Mannheim Gmbh	Verfahren zur herstellung von poroesen tabletten
US3939253A (en)	1973-11-02	1976-02-17	Interx Research Corporation	Novel, transient pro-drug forms of l-dopa useful in the treatment of parkinson's disease
JPS5157813A (en)	1974-11-14	1976-05-20	Sankyo Co	Ll dooba mataha sonojudotaiseizaino seiho
US4035507A (en)	1975-04-17	1977-07-12	Interx Research Corporation	Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease
US4916151A (en)	1985-12-05	1990-04-10	Merrell Dow Pharmaceuticals Inc.	Method of treating parkinson's syndrome
US4663349A (en)	1985-12-30	1987-05-05	Merck & Co., Inc.	Rectally absorbable form of L-dopa
US4771073A (en) *	1985-12-30	1988-09-13	Merck & Co., Inc.	Rectally absorbable form of L-dopa
DE252290T1 (de)	1986-06-10	1988-06-09	Chiesi Farmaceutici S.P.A., Parma	Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
IL92952A (en)	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
MY110880A (en)	1991-01-30	1999-06-30	The Wellcome Foundation Ltd	Water-dispersible tablets
US5354885A (en) *	1992-12-24	1994-10-11	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Process for preparing ethyl ester of L-DOPA
US5607969A (en)	1992-12-24	1997-03-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem	L-DOPA ethyl ester to treat Parkinson's disease
US5840756A (en) *	1995-07-21	1998-11-24	Teva Pharmaceutical Industries Ltd.	Pharmaceutical composition of L-DOPA ester
NZ512027A (en)	1998-11-10	2004-04-30	Teva Pharma	Dispersible compositions containing L-dopa ethyl ester

1999
- 1999-11-10 NZ NZ512027A patent/NZ512027A/en not_active Application Discontinuation
- 1999-11-10 IL IL14307199A patent/IL143071A0/xx unknown
- 1999-11-10 HK HK02102206.4A patent/HK1041441A1/zh unknown
- 1999-11-10 JP JP2000580614A patent/JP2002529407A/ja active Pending
- 1999-11-10 EP EP99960257A patent/EP1135118A1/en not_active Withdrawn
- 1999-11-10 HU HU0104586A patent/HUP0104586A3/hu unknown
- 1999-11-10 US US09/437,699 patent/US6376545B1/en not_active Expired - Fee Related
- 1999-11-10 CA CA002350304A patent/CA2350304A1/en not_active Abandoned
- 1999-11-10 AU AU17168/00A patent/AU764742B2/en not_active Ceased
- 1999-11-10 CN CN99814098A patent/CN1329487A/zh active Pending
- 1999-11-10 WO PCT/US1999/026546 patent/WO2000027385A1/en not_active Ceased
2001
- 2001-05-02 ZA ZA200103527A patent/ZA200103527B/en unknown
- 2001-05-08 NO NO20012265A patent/NO20012265L/no unknown
2002
- 2002-02-25 US US10/083,959 patent/US6703424B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6376545B1 (en)	2002-04-23
AU764742B2 (en)	2003-08-28
HUP0104586A2 (en)	2002-06-29
NZ512027A (en)	2004-04-30
CA2350304A1 (en)	2000-05-18
US6703424B2 (en)	2004-03-09
CN1329487A (zh)	2002-01-02
IL143071A0 (en)	2002-04-21
NO20012265D0 (no)	2001-05-08
JP2002529407A (ja)	2002-09-10
HUP0104586A3 (en)	2002-12-28
EP1135118A1 (en)	2001-09-26
US20020151589A1 (en)	2002-10-17
AU1716800A (en)	2000-05-29
WO2000027385A1 (en)	2000-05-18
ZA200103527B (en)	2002-05-09
HK1041441A1 (zh)	2002-07-12

Publication	Publication Date	Title
NO20012265L (no)	2001-07-03	Dispergerbare preparater inneholdende L-DOPA-ethylester
IS2325B (is)	2007-12-15	Örgerðar samsetningar epleróns
MA24473A1 (fr)	1998-10-01	Formulations
IS5555A (is)	2000-06-30	Selekoxib lyfjablöndur
ID30031A (id)	2001-11-01	Formulasi-formulasi agrokimia
ID23546A (id)	2000-05-04	Formulasi-formulasi ziprasidon
ID23299A (id)	2000-04-05	Formulasi-formulasi farmasi
DK0921796T3 (da)	2001-07-16	Tetrahydrolipstatinholdige præparater
NO20004240L (no)	2000-10-18	Formuleringer
IS6040A (is)	2001-08-07	Valdekoxib efnablöndur
ATE224703T1 (de)	2002-10-15	Brauseformulierungen
PT1130966E (pt)	2005-04-29	Formulacoes antiparasitarias
NO20010046L (no)	2001-03-02	Dolastatin-15-derivater
DK1001813T3 (da)	2003-07-28	Farmaceutiske formuleringer indeholdende voriconazol
DE69823830D1 (de)	2004-06-17	Dermatologische zubereitungen
NO20000231D0 (no)	2000-01-17	Dolastatin-15-derivater
DE60029602D1 (de)	2006-09-07	Lipasehemmer enthaltende dispersionsformulierungen
DE59902101D1 (de)	2002-08-29	Pigmentpräparationen
DE69805807D1 (de)	2002-07-11	Mikrobiozide n-sulfonylglycin-alkynyloxyphenethylamid-derivate
IS6398A (is)	2002-05-27	Lyfjablöndur
ATE357237T1 (de)	2007-04-15	Formulierungen enthaltend cefuroxim-axetil
ATE281836T1 (de)	2004-11-15	Stabilisierte tibolone zubereitungen
ATE298576T1 (de)	2005-07-15	Arzneizubereitungen
ATE246494T1 (de)	2003-08-15	Brausezubereitungen
PT895782E (pt)	2005-02-28	Preparados farmaceuticos de cilansetron estabilizados contra racemizacao